ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Current Price
0,676
Gebot
0,6601
Fragen
0,676
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Handelsende
0,676
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
-
Durchschnittliches Volumen (3 Mio.)
-
Finanzvolumen
-
VWAP
-

VICL Neueste Nachrichten

Vical Stockholders Approve Reverse Stock Split and Merger with Brickell

•  Merger Transaction Expected to Close August 31, 2019 SAN DIEGO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Vical Incorporated (“Vical”) (Nasdaq:VICL) announced that its stockholders voted to approve...

Moore Kuehn, PLLC Encourages Vical Incorporated (VICL), ASV Holdings, Inc. (ASV), PCM, Inc. (PCMI), WageWorks, Inc. (WAGE), a...

Moore Kuehn, PLLC Encourages Vical Incorporated (VICL), ASV Holdings, Inc. (ASV), PCM, Inc. (PCMI), WageWorks, Inc. (WAGE), and Acacia Communications, Inc. (ACIA) Investors to Contact Firm PR...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Vical Incorporated Acquisition

SHAREHOLDER ALERT: WeissLaw LLP Investigates Vical Incorporated Acquisition PR Newswire NEW YORK, June 12, 2019 NEW YORK, June 12, 2019 /PRNewswire/ -- WeissLaw LLP  is investigating possible...

Vical and Brickell Announce Merger Agreement

Combined Company Well-Capitalized with Approximately $35 Million in Cash and up to $25 Million in Near-Term R&D FundingPivotal Phase 3 Clinical Trials for Brickell’s Lead Product Candidate...

Vical to Discontinue Clinical Development of VL-2397 as it Considers Near Term Strategic Alternatives

SAN DIEGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that it has decided to discontinue the Phase 2 clinical trial of VL‑2397 that was initiated in the...

Vical Reports Third Quarter 2018 Financial and Operational Results

SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended September 30, 2018. Net loss for the third quarter of...

Vical to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

SAN DIEGO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on...

Vical Reports Second Quarter 2018 Financial and Operational Results

SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended June 30, 2018. Net loss for the second quarter of 2018...

Vical Announces Review of Potential Strategic Transactions

SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that its Board of Directors plans to explore a range of strategic options to enhance shareholder...

Vical Reports Phase 2 Trial of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint

SAN DIEGO, June 11, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced top-line results from a randomized, double-blind, placebo-controlled, Phase 2 clinical study of its...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

VICL - Frequently Asked Questions (FAQ)

What is the current Vical share price?
The current share price of Vical is US$ 0,676
What is the 1 year trading range for Vical share price?
Vical has traded in the range of US$ 0,00 to US$ 0,00 during the past year
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
SLXNSilexion Therapeutics Corporation
US$ 1,2108
(108,76%)
172,27M
RNAZTransCode Therapeutics Inc
US$ 12,5687
(84,02%)
16,78M
YIBOPlanet Image International Ltd
US$ 4,84
(57,14%)
48,15M
BACKIMAC Holdings Inc
US$ 1,175
(41,74%)
52,6M
TRIBTrinity Biotech PLC
US$ 1,069
(40,66%)
98,61M
LPTXLeap Therapeutics Inc
US$ 0,6476
(-71,22%)
7,73M
STSSSharps Technology Inc
US$ 0,4426
(-69,68%)
11,44M
SABSSAB Biotherapeutics Inc
US$ 2,2109
(-49,29%)
936,66k
MGOLMGO Global Inc
US$ 0,173
(-38,87%)
14,48M
INKTMiNK Therapeutics Inc
US$ 6,21
(-29,74%)
64,93k
NVDANVIDIA Corporation
US$ 121,32
(2,45%)
235,87M
HEPAHepion Pharmaceuticals Inc
US$ 0,2166
(31,27%)
230,95M
SLXNSilexion Therapeutics Corporation
US$ 1,2108
(108,76%)
172,27M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,4928
(19,58%)
125,42M
TRIBTrinity Biotech PLC
US$ 1,069
(40,66%)
98,61M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen